Shanghai Bio-heart Biological Technology Co., Ltd.
Shanghai Bio-heart Biological Technology Co., Ltd. (HKSE: 2185) is trading at HK$1.44, about ₹18 at today's HKD/INR rate, as of 24 Sep 2026, 11:39 PM ET, up 3.61% today. Indian residents can buy Shanghai Bio-heart Biological Technology from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$1.39
Today's high
HK$1.44
52 week low
HK$1.35
52 week high
HK$9.10
2185 opened at HK$1.39, closed previously at HK$1.39, and has traded between HK$1.35 and HK$9.10 over the past 52 weeks.
About
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
Key statistics
Avg. volume
285.21K
Market cap
HK$338.23M
P/E Ratio
-3.96
Price-to-sales ratio
7.64
Enterprise value
CN¥208.36M
Free cash flow yield
-22.56%
Debt-to-equity ratio
0.03
Return on equity
-17.76%
ROIC
-8.19%
Beta
0.09
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥43.77M
Earnings per share
-CN¥0.28
Free cash flow
-CN¥72.91M
Net profit margin
-196.41%
Gross margin
-2.29%
EBITDA
-CN¥52.13M
Revenue growth
—
Similar securities
This is not an investment recommendation
How to buy Shanghai Bio-heart Biological Technology from India
Indian residents can buy Shanghai Bio-heart Biological Technology shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Shanghai Bio-heart Biological Technology and place an order
Find Shanghai Bio-heart Biological Technology by name or by its ticker, 2185, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Shanghai Bio-heart Biological Technology trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Shanghai Bio-heart Biological Technology position in HKD and INR. Shanghai Bio-heart Biological Technology pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Shanghai Bio-heart Biological Technology from India
Trading and taxes when buying Shanghai Bio-heart Biological Technology from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneShanghai Bio-heart Biological Technology does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Shanghai Bio-heart Biological Technology stock?
Yes. Shanghai Bio-heart Biological Technology (2185) has been listed on the Hong Kong Stock Exchange since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Shanghai Bio-heart Biological Technology share cost in rupees?
One Shanghai Bio-heart Biological Technology share is HK$1.44 — about ₹18 at an HKD/INR rate of 12.23 on 25 Sep 2026. Both the Shanghai Bio-heart Biological Technology price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Shanghai Bio-heart Biological Technology from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Shanghai Bio-heart Biological Technology?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Shanghai Bio-heart Biological Technology shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Shanghai Bio-heart Biological Technology price. Paasa issues a capital-gains statement for your return.
Does Shanghai Bio-heart Biological Technology pay a dividend?
No. Shanghai Bio-heart Biological Technology does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Shanghai Bio-heart Biological Technology from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Shanghai Bio-heart Biological Technology a Hong Kong SAR China company, and does that change how it is taxed?
Shanghai Bio-heart Biological Technology trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Shanghai Bio-heart Biological Technology trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Shanghai Bio-heart Biological Technology shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Shanghai Bio-heart Biological Technology holding, its cost and its closing value.
How do I sell Shanghai Bio-heart Biological Technology and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.